RT期刊文章SR电子T1血清肌钙蛋白水平在急性缺血性中风患者识别伴随内脏梗死(p2.3 - 030)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p2.3补充92 - 030签证官是15 A1 Idrees Azher A1 Ashutosh Kaushal 首页A1安德鲁Chang A1 (Shawna切割A1布莱恩Mac Grory A1蒂娜伯顿A1凯蒂Dakay A1布拉德福德·汤普森A1迈克尔Reznik A1琳达温德尔A1尼古拉斯·波特A1阿里Mahta A1亚历山大merkle A1 Hooman Kamel A1米切尔艾尔金德A1 Mahesh Jayaraman A1迈克尔Atalay A1凯伦富里A1 Shadi Yaghi年2019 UL //www.ez-admanager.com/content/92/15_supplement/p2.3 - 030. -文摘AB目的:确定血清肌钙蛋白水平之间的关系的时候中风和内脏缺血性中风组梗塞。背景:缺血性中风患者的cardioembolic起源、发展的风险内脏(肾、脾)梗塞。设计/方法:数据抽象从单中心前瞻性缺血性中风数据库超过18个月,包括缺血性中风患者进行了对比增强CT腹部和骨盆在一年内用于临床的中风。主要因素是肌钙蛋白水平≥0.1 ng / mL。主要结果是内脏梗死(肾和脾)CT腹部和骨盆。单变量和多变量逻辑回归模型被用来估计的优势比和95%置信区间(或者,95% CI)协会的肌钙蛋白与内脏梗死前后调整人口结构和危险因素(高血压、糖尿病、高脂血症、中风历史、充血性心力衰竭、冠心病、和吸烟),署分数,和中风亚型(cardioembolic、栓塞性中风的未知来源,并定义non-cardioembolic亚型)。结果:1234缺血性中风患者,259例有资格内脏CT。血清肌钙蛋白水平入院时测定237例(93.3%)。25内脏梗死患者:16个肾,7脾,2两。在单变量模型中,有一个协会之间的血清肌钙蛋白水平和存在的内脏梗死(39.1%比15.0%,p = 0.008),它保存在多变量模型(或3.65 95%可信区间1.46 - 9.17,p = 0.006)。毫不奇怪,有一个内脏梗死和cardioembolic中风亚型之间的联系(或7.88 95%可信区间1.01 - 61.87,p = 0.05)和、因亚型(95%可信区间0.95 - 60.15或7.55,p = 0.056),相比non-cardioembolic中风亚型。结论:缺血性中风患者,血清肌钙蛋白水平升高可能有助于识别患者伴随的内脏梗死。需要更大规模的研究来证实我们的发现。披露:Azher博士没有披露。 Dr. Kaushal has nothing to disclose. Dr. Chang has nothing to disclose. Dr. Cutting has nothing to disclose. Dr. Mac Grory has nothing to disclose. Dr. Burton has nothing to disclose. Dr. Dakay has nothing to disclose. Dr. Thompson has nothing to disclose. Dr. Reznik has nothing to disclose. Dr. Wendell has nothing to disclose. Dr. Potter has nothing to disclose. Dr. Mahta has nothing to disclose. Dr. Merkler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GLG. Dr. Kamel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roivant Sciences, Medtronic, BMS, and Roche Diagnostics Corporation. Dr. Kamel has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Kamel has received research support from NIH/NINDS. Dr. Elkind has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott, Vascular Dynamics, Merck/Organon Auxilium, and Sorin. Dr. Elkind has received research support from BMS-Pfizer Alliance, and Roche. Dr. Jayaraman has nothing to disclose. Dr. Atalay has nothing to disclose. Dr. Furie has nothing to disclose. Dr. Yaghi has nothing to disclose.